S&P/ASX 200 Index (ASX: XJO) shares rose 2.77% and delivered total returns, including dividends, of 7% in FY26.
On The Bull this week, Remo Greco from Sanlam Private Wealth shares his insights on three ASX 200 shares for FY27.
Let's take a look.
Image source: Getty Images
Dexus Convenience Retail REIT (ASX: DXC)
The Dexus Convenience Retail REIT fell 14.8% to finish at $2.59 per share on 30 June.
Greco has a buy rating on this ASX real estate investment trust (REIT).
Greco said:
This real estate investment trust owns service stations and convenience retail assets, mostly on Australia's eastern seaboard.
The fund's portfolio was valued at about $760 million on December 31, 2025. The company was recently trading at a significant discount to net tangible assets (NTA) and was yielding about 8 per cent.
The trust has an attractive development pipeline, modest debt and recently increased its buy-back target. Importantly, the NTA is supported by recent asset sales of 1.5 per cent above valuation.
Recently announced capital gains tax changes make the company's assets appealing to self managed super funds looking for reliable income generating assets.
DXC is a solid defensive play in the current environment.
BHP Group Ltd (ASX: BHP)
The BHP share price soared 62% to finish FY26 at $59.40 last Tuesday.
Greco has a hold rating on the ASX 200 mining share for FY27.
He said:
Several disappointing events have led us to downgrade BHP to a hold.
Cost over-runs at its Jansen stage 2 potash project in Canada lifts the investment cost by about $US2 billion to $US6.9 billion. Possible industrial action, although averted in June, may re-ignite at the company's iron ore operations in the Pilbara region of Western Australia.
Any industrial action may impact stock performance.
Longer term, we like BHP's exposure to copper – the key metal of the future.
As reported in our best-performing commodities of FY26 article, the copper price rose by 18% while iron ore increased 7% over the year.
Resmed CDI (ASX: RMD)
The Resmed share price fell 26.6% to $28.88 on 30 June amid a broader healthcare sector rout in FY26.
Greco has a sell rating on this ASX 200 healthcare share, and commented:
The company makes medical devices to treat sleep apnoea. The company lifted revenue by 11 per cent in the third quarter of financial year 2026 when compared to the prior corresponding period.
In my view, GLP-1 weight loss drugs may reduce the incidence of sleep apnoea.
ResMed's share price has been volatile in the past 12 months as investors weighed up the company's outlook in light of popular GLP-1 drugs.
The shares have risen from $25.84 on June 3 to trade at $29.37 on July 2.
It may be prudent to sell some shares prior to RMD's full year result.
Resmed is due to release its 4Q FY26 results on 7 August.
